首页> 外文期刊>Balkan journal of medical genetics: BJMG >TWIST1 Gene expression as a biomarker for predicting primary doxorubicin resistance in breast cancer
【24h】

TWIST1 Gene expression as a biomarker for predicting primary doxorubicin resistance in breast cancer

机译:Twist1基因表达作为预测乳腺癌原发性多柔比蛋白抗性的生物标志物

获取原文
           

摘要

Doxorubicin is one of the most commonly used chemotherapeutic agents for adjuvant chemotherapy of breast cancer. In the studies focused on finding biomarkers to predict the response of the patients and tumors to the drugs used, the Twist transcription factor has been suggested as a candidate biomarker for predicting chemo-resistance of breast tumors. In this study, we aimed to investigate the relationship between TWIST transcription factor expression and the effectiveness of doxorubicin treatment on directly taken primary tumor samples from chemotherapy-naive breast cancer patients. Twenty-six primary breast tumor samples taken from 26 different breast cancer patients were included in this study. Adenosine triphosphate tumor chemo-sensitivity assay (ATP-TCA) has been used to determine tumor response to doxorubicin and real-time reverse-transcription polymerase chain reaction (RT-PCR) was used for analyzing the TWIST1 gene expression of tumors. There was a significant difference in TWIST gene expression between responder and non responder tumors (p 0.05). The TWIST gene expression of the drug-resistant group was higher than the responsive group. This difference was not dependent on the histopathological features of tumors. In conclusion, compatible with earlier studies that have been performed with cell lines, the current study supports the role of higher TWIST gene expression as a biomarker for predicting the response of breast tumors to chemo-therapeutic agent doxorubicin.
机译:多柔比星是乳腺癌佐剂化疗最常用的化学治疗剂之一。在研究的重点是寻找生物标志物预测患者和肿瘤对所用药物的反应,已经提出了扭曲转录因子作为用于预测乳腺肿瘤的化学抗性的候选生物标志物。在这项研究中,我们旨在探讨扭曲转录因子表达与多柔比蛋白治疗的有效性对直接采用的乳腺癌乳腺癌患者的关系。本研究包括来自26种不同乳腺癌患者的二十六种原发性乳腺肿瘤样本。腺苷三磷酸肿瘤化学敏感性测定(ATP-TCA)已经用于确定对多柔比星的肿瘤反应,并且使用实时逆转录聚合酶链反应(RT-PCR)用于分析肿瘤的Twist1基因表达。响应者和非响应者肿瘤之间的扭曲基因表达存在显着差异(P <0.05)。耐药组的扭曲基因表达高于响应基团。这种差异不依赖于肿瘤的组织病理学特征。总之,与已经用细胞系进行的早期研究相容,目前的研究支持较高的扭曲基因表达作为预测乳腺肿瘤对化学治疗剂的生物标志物的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号